Advertisement

European Journal of Clinical Pharmacology

, Volume 72, Issue 9, pp 1051–1058 | Cite as

Comparative efficacy of nonhormonal drugs on menopausal hot flashes

  • Lujin Li
  • Ling Xu
  • Junyi Wu
  • Lidan Dong
  • Shuiyu Zhao
  • Qingshan Zheng
Pharmacodynamics

Abstract

Purpose

The effects of nonhormonal drugs on menopausal hot flashes are still not well quantified. We therefore did a model-based meta-analysis (MBMA) to quantitate and compare the efficacy features of nonhormonal drugs on menopausal hot flashes.

Methods

Literature was searched in the public databases to extract data of clinical trials on nonhormonal drugs, including selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), gabapentin, clonidine, and soy isoflavones. Pharmacodynamic models were used for the quantitative analysis of each drug.

Results

Thirty-nine studies were included in the analysis. The results revealed a classic pharmacodynamic maximal effect (Emax) model could describe the time course of hot-flash reduction by nonhormonal drugs. After deducting placebo effects, the Emax of SSRIs/SNRIs, gabapentin, clonidine, and soy isoflavones was 13.9 %, 14.8 %, 18.5 %, and 25.0 %, respectively. The time to achieve half of the maximal effect (ET50) of SSRIs/SNRIs, gabapentin, clonidine, and soy isoflavones was 0.18 weeks, 0 weeks, 0 weeks, and 11.6 weeks, respectively. The results showed that SSRIs/SNRIs, gabapentin, and clonidine had a rapid onset, which could reach the maximum effect immediately. However, the onset of soy isoflavones was very slow, and a duration of 16.6 weeks was needed to surpass the efficacy of paroxetine (a type of SSRIs).

Conclusions

The information provided in this study can be used as valuable supplementary information for treatment guidelines of nonhormonal drugs on menopausal hot flashes.

Keywords

Menopause Hot flashes Nonhormonal agents Model-based meta-analysis 

Notes

Acknowledgments

The authors especially thank Christine M. Derzko (St. Michael’s Hospital, University of Toronto) for valuable contributions to the manuscript. This study was supported by Shanghai Municipal Science and Technology Commission (14CG40, ZY3-CCCX-3-1001) and the Notional Natural Science Funds (81303279).

Compliance with ethical standards

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

Lujin Li designed the work, analyzed data, and wrote the paper. Ling Xu searched papers and analyzed data. Junyi Wu, Lidan Dong, and Shuiyu Zhao contributed to data extraction and cleaning. Qingshan Zheng participated in conception and design of the work and revised the paper critically for important intellectual content.

Supplementary material

228_2016_2090_MOESM1_ESM.doc (1.5 mb)
ESM 1 (DOC 1504 kb)

References

  1. 1.
    (2015) Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 22(11):1155–1174Google Scholar
  2. 2.
    Kronenberg F (1990) Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 592:52–86, discussion 123–133CrossRefPubMedGoogle Scholar
  3. 3.
    Ma J, Drieling R, Stafford RS (2006) US women desire greater professional guidance on hormone and alternative therapies for menopause symptom management. Menopause 13(3):506–516CrossRefPubMedGoogle Scholar
  4. 4.
    Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297(13):1465–1477CrossRefPubMedGoogle Scholar
  5. 5.
    Orleans RJ, Li L, Kim MJ, Jia G, Mahboob S, Lisa S (2014) FDA approval of paroxetine for menopausal hot flushes. N Engl J Med 370(19):1777–1779CrossRefPubMedGoogle Scholar
  6. 6.
    Mould DR (2012) Model-based meta-analysis: an important tool for making quantitative decisions during drug development. Clin Pharmacol Ther 92(3):283–286CrossRefPubMedGoogle Scholar
  7. 7.
    Boucher M, Bennetts M (2016) The Many Flavors of Model-Based Meta-Analysis: Part I—Introduction and Landmark Data. CPT: Pharmacometrics Syst Pharmacol 5(2):54–64Google Scholar
  8. 8.
    Mandema JW, Salinger DH, Baumgartner SW (2011) A Dose–Response Meta-Analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid Arthritis Clinical Pharmacology & Therapeutics 90(6):828–835Google Scholar
  9. 9.
    Ren YP, Xie RJ, Marshall S, Li L, Zhou TY, Lu W (2015) Model-based meta-analysis of the effects of nonselective and α1-selective GABAA receptor agonists in healthy volunteers. Eur J Clin Pharmacol 71(10):1209–1221CrossRefPubMedGoogle Scholar
  10. 10.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRefPubMedGoogle Scholar
  11. 11.
    Deecher DC, Dorries K (2007) Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 10(6):247–257CrossRefPubMedGoogle Scholar
  12. 12.
    Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L (2006) Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 295(17):2057–2071CrossRefPubMedGoogle Scholar
  13. 13.
    (2003) Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms –recommendations for clinical evaluation. FDAGoogle Scholar
  14. 14.
    Li L, Lv Y, Xu L, Zheng Q (2015) Quantitative efficacy of soy isoflavones on menopausal hot flashes. Br J Clin Pharmacol 79(4):593–604CrossRefPubMedGoogle Scholar
  15. 15.
    Manson JE, Kaunitz AM (2016) Menopause Management-Getting Clinical Care Back on Track. N Engl J Med 374(9):803–806CrossRefPubMedGoogle Scholar
  16. 16.
    (2015) Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 22(11):1155–1172Google Scholar
  17. 17.
    Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC (2004) Endometrial effects of long-term treatment with phytoestrogens: a randomized doubleblind, placebo-controlled study. Fertil Steril 82:145–148CrossRefPubMedGoogle Scholar
  18. 18.
    Setchell KD, Brown NM, Lydeking Olsen E (2002) The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 132(12):3577–3584PubMedGoogle Scholar
  19. 19.
    Boucher M (2012) Imputation of missing variance data using nonlinear mixed effects modelling to enable an inverse variance weighted meta-analysis of summary-level longitudinal data: a case study. Pharm Stat 11(4):318–324CrossRefPubMedGoogle Scholar
  20. 20.
    Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ (2006) A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 59(4):342–353CrossRefPubMedGoogle Scholar
  21. 21.
    Ahn JE, French JL (2010) Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn 37(2):179–201CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Center for Drug Clinical ResearchShanghai University of Traditional Chinese MedicineShanghaiChina

Personalised recommendations